Work

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

Year: 2005

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Blood

DOI: 10.1182/blood.v106.11.4076.4076

Authors: Jerry Sherman Powell, Thierry Lambert, F. Hernández Navarro, Michael Recht, Sharon T. Sullivan, Chandrasekhar Udata, Leslie C. Lilly, David A. Roth, The rFIX-R Study Group

Institutions: University of California Davis Medical Center, Assistance Publique – Hôpitaux de Paris, Bicêtre Hospital, Hospital Universitario La Paz, Phoenix Children's Hospital, Wyeth

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2554368482

FWCI:

Cites:

Cited by:

Related to: 10